AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Thyrotropin receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P16473

UPID:

TSHR_HUMAN

Alternative names:

Thyroid-stimulating hormone receptor

Alternative UPACC:

P16473; A0PJU7; F5GYU5; G3V2A9; Q16503; Q8TB90; Q96GT6; Q9P1V4; Q9ULA3; Q9UPH3

Background:

The Thyrotropin receptor, also known as the Thyroid-stimulating hormone receptor, plays a pivotal role in thyroid cell metabolism. It acts as a receptor for TSH or thyrotropin, and for the heterodimeric glycoprotein hormone thyrostimulin, mediating its activity through G proteins which activate adenylate cyclase.

Therapeutic significance:

Linked to conditions such as Hypothyroidism, congenital, non-goitrous, 1, Familial gestational hyperthyroidism, and Hyperthyroidism, non-autoimmune, the Thyrotropin receptor's involvement in these diseases underscores its potential as a target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.